Among the renewed services, Chain Drug Consortium participating pharmacies will be able to utilize the Emdeon Clinical Exchange eRx Network, which is designed to enhance interoperable information exchange and help improve patient safety and clinical outcomes.
Teva Pharmaceutical and Perrigo Co. announced the launch of the generic equivalent to Temodar (temozolomide). Teva will manufacture, market and distribute the product in the United States, and both companies will equally share in the cost and profitability of the product in the country.
Perrigo Co. announced that it has received final approval from the Food and Drug Administration for its abbreviated new drug applications for fluocinolone acetonide scalp oil, 0.01%, the generic equivalent to Derma-Smoothe/FS Scalp Oil, and fluocinolone acetonide topical oil, 0.01%, the generic equivalent to Derma-Smoothe/FS Body Oil.
As pharmacy evolves from medication dispensing to a key component of the healthcare system, strengthening the pharmacist's role in health care was the dominant theme at a recent conference sponsored by a coalition of pharmacy groups.
VoicePort announced the launch of its Medication Synchronization automated solution with two U. S. pharmacy chain clients and are in final stage negotiations with several others in support of helping pharmacies deliver increased patient health-and-wellness.
As part of its continued commitment to supporting future pharmacists, Cardinal Health announced that six pharmacy schools across the country will receive more than $625,000 in funding through the Cardinal Health Pharmacy Scholarship Program.
The Supreme Court usually has a lot on its plate in any given year, but this year's term included a pretty big case for the pharmaceutical industry: the Federal Trade Commission v. Actavis, which concerned legal settlements between branded and generic drug makers that often occur when the latter attempts to market a generic drug before the former's patents have expired.